Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
External Quality Assurance Schemes (EQUASs) and Inter-laboratory Comparison Investigations (ICIs) for human biomonitoring of polycyclic aromatic hydrocarbon (PAH) biomarkers in urine as part of the quality assurance programme under HBM4EU.
Nübler S, Esteban López M, Castaño A, Mol HGJ, Müller J, Schäfer M, Haji-Abbas-Zarrabi K, Hajslova J, Pulkrabova J, Dvorakova D, Urbancova K, Koch HM, Antignac JP, Sakhi AK, Vorkamp K, Burkhardt T, Scherer M, Göen T. Nübler S, et al. Among authors: burkhardt t. Int J Hyg Environ Health. 2023 May;250:114169. doi: 10.1016/j.ijheh.2023.114169. Epub 2023 Apr 24. Int J Hyg Environ Health. 2023. PMID: 37099846
Adverse Childhood Experiences, Resilience, and Cardiovascular Disease in Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study.
Schwartz LF, Stratton KL, Leisenring WM, Marron Rodriguez S, Alston S, McDonald A, Vukadinovich C, Rinehart D, Oeffinger KC, Chow EJ, Krull KR, Brinkman TM, Nathan PC, Tan MM, McCrae JS, Burkhardt T, Ness KK, Armstrong GT, Henderson TO. Schwartz LF, et al. Among authors: burkhardt t. Cancer Epidemiol Biomarkers Prev. 2024 May 13. doi: 10.1158/1055-9965.EPI-24-0249. Online ahead of print. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 38738881
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.
Körper S, Grüner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R, Zacharowski K, Spieth P, Tonn T, Rosenberger P, Paul G, Pilch J, Schwäble J, Bakchoul T, Thiele T, Knörlein J, Dollinger MM, Krebs J, Bentz M, Corman VM, Kilalic D, Schmidtke-Schrezenmeier G, Lepper PM, Ernst L, Wulf H, Ulrich A, Weiss M, Kruse JM, Burkhardt T, Müller R, Klüter H, Schmidt M, Jahrsdörfer B, Lotfi R, Rojewski M, Appl T, Mayer B, Schnecko P, Seifried E, Schrezenmeier H. Körper S, et al. Among authors: burkhardt t. J Clin Invest. 2022 Dec 15;132(24):e163657. doi: 10.1172/JCI163657. J Clin Invest. 2022. PMID: 36326824 Free PMC article. Clinical Trial.
163 results